Comparative Pharmacology
Head-to-head clinical analysis: LARYNG O JET KIT versus VIVACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNG O JET KIT versus VIVACAINE.
LARYNG-O-JET KIT vs VIVACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
VIVACAINE is a local anesthetic that blocks the generation and conduction of nerve impulses by decreasing sodium ion permeability across the neuronal membrane.
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
5-10 mL of 1% solution (50-100 mg) via submucosal infiltration or nerve block; maximum 500 mg per procedure.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect.
Terminal elimination half-life: 6–8 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 12–15 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 10–12 hours.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 85–90% of elimination, with about 10–15% excreted in feces via biliary clearance. Less than 2% of the dose is recovered unchanged in urine; the remainder is as glucuronide conjugates and other metabolites.
Category C
Category C
Local Anesthetic
Local Anesthetic